See also this year's filing and all EDGAR filings for this company.
PDF Report 0001070494_2019_ACADIA_PHARMACEUTICALS_INC.pdf
Logs
| warning | Large missing amount for aggregate "Revenues" added to remainder. | industry.us_generic | {'missing_ratio': inf, 'aggregate_val': 223807000, 'exp_sum': 0, 'exp_to_value': {'remainder_Revenues': 0}} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.026791783016213173, 'aggregate_val': 474347000, 'exp_sum': 461970000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 265758000, 'ResearchAndDevelopmentExpense': 187163000, 'remainder_Expenses': 9049000}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001070494, ACADIA PHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 526,106,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 4,062,000 |
| 2 | PropertyPlantAndEquipmentNet | 3,309,000 |
| 3 | remainder_Assets | 6,725,000 |
| 4 | LiabilitiesCurrent | 59,565,000 |
| 5 | LiabilitiesNoncurrent | 1,558,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 265,758,000 |
| 9 | ResearchAndDevelopmentExpense | 187,163,000 |
| 10 | remainder_Expenses | 21,426,000 |
| 11 | remainder_Revenues | 223,807,000 |
| 12 | remainder_NetIncome | 5,348,000 |
| 13 | remainder_ComprehensiveNetIncome | 27,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 540,202,000 |
| 1 | Liabilities | 61,123,000 |
| 2 | Expenses | 474,347,000 |
| 3 | Revenues | 223,807,000 |
| 4 | StockholdersEquity | 479,079,000 |
| 5 | NetIncome | -245,192,000 |
| 6 | ComprehensiveNetIncome | -245,178,500 |
| 7 | BaseVar | 652,427,000 |
| 8 | EconomicCapitalRatio | 1.93 |
Edgar->Model Mapping
Feature Distribution
Change over Time
